Cantuzumab（Cat No.:I041520）is an investigational monoclonal antibody designed to target and bind to the tumor-associated antigen CD56, which is expressed on various cancer cells, including those in small cell lung cancer and neuroblastoma. By targeting CD56, Cantuzumab aims to inhibit tumor growth and potentially improve the immune system’s ability to recognize and destroy cancer cells. It has been studied in combination with chemotherapy or other treatments in clinical trials. While early results have shown some promise, further research is needed to fully assess Cantuzumab’s safety, efficacy, and potential as a cancer therapy.
